Extensive-stage small cell lung cancer (ES-SCLC)

news

AstraZeneca immunotherapy could boost lung cancer survival

3 June 2024 | By Catherine Eckford (European Pharmaceutical Review)

Over half of patients were alive three years post-treatment with the monoclonal antibody (mAb) in AstraZeneca’s Phase III trial, data shows.

news

FDA approves Amgen T-cell engager for small cell lung cancer

17 May 2024 | By Caroline Peachey (European Pharmaceutical Review)

Amgen’s Imdelltra™, previously known as tarlatamab, is approved for the treatment of adult patients with advanced small cell lung cancer. 

news

Serplulimab increases survival in small cell lung cancer patients

30 September 2022 | By Catherine Eckford (European Pharmaceutical Review)

Hansizhuang (serplulimab), the world's first anti-PD-1 monoclonal antibody (mAb) treatment for extensive-stage small cell lung cancer (ES-SCLC), enhanced survival rates compared to chemotherapy, and is projected to be the leading immunotherapy for the disease in the next five years.

news

Imfinzi^™ plus chemotherapy triples small cell lung cancer survival

20 September 2021 | By Anna Begley (European Pharmaceutical Review)

Roughly 17.6 percent of patients treated with Imfinzi plus chemotherapy were alive at three years, versus 5.8 percent of chemotherapy patients.

news

Imfinzi approved in EU to treat extensive-stage small cell lung cancer

11 September 2020 | By Victoria Rees (European Pharmaceutical Review)

Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.